At a Beijing research hospital, scientists have fashioned a single molecular tool that can both find and destroy kidney cancer tumors — a convergence of diagnosis and therapy that medicine has long sought. The compound targets a protein that kidney cancer cells overproduce, allowing clinicians to first map the disease and then deliver radiation with unusual precision. For patients whose cancers have outrun immunotherapy and surgery, this approach represents not merely a new drug but a new philosophy of treatment — one that listens to the tumor's own biology before striking it.
New radiotheranostic pair shows promise for metastatic kidney cancer treatment
Patients with metastatic kidney cancer who had progressed on standard therapy participated in clinical trials; gastric toxicity was observed in treatment.
Tumors lit up with very high uptake, and early results suggest a new path forward
Mark
So this is a treatment that both finds the cancer and treats it at the same time?
Mimi
Essentially, yes. The diagnostic version lights up tumors so you can see where they are. If they light up, you know the therapeutic version will likely work on those same spots.
Luke
But they're using two different radioactive isotopes, right? So it's not literally the same molecule doing both jobs in one patient.
Mimi
Correct. You image first with one isotope, then treat with another. Same targeting molecule, different radioactive payload.
Mark
Why does that matter—why not just use the therapeutic one from the start?
Luke
Because you'd be exposing patients to radiation therapy without knowing if their tumors actually express the target. This way you confirm uptake first.
Mimi
Exactly. And the imaging data also gives you dosimetry information—how much radiation different organs will receive during treatment.
Mark
The stomach toxicity they found—is that a deal-breaker?
Luke
Not necessarily. They identified it in a small early-stage trial. It's a known problem in radiotherapy, and now they know where to focus engineering efforts.
Mimi
The fact that kidneys, liver, and pancreas showed no toxicity is significant for kidney cancer patients, since their remaining kidney function is often already compromised.
Mark
So what happens next?
Luke
They need to redesign the compound to reduce gastric uptake while keeping tumor uptake high. That's the work ahead.
Mimi
And they'll likely expand the trial to more patients to confirm these early results hold up.
O Pulso
- Patients with metastatic kidney cancer who have exhausted standard therapies face a near-empty medicine cabinet, making the search for alternatives genuinely urgent.
- The new compound, 68Ga/177Lu-NYM096, exploits a protein overexpressed on kidney cancer cells to deliver imaging and radiation therapy through the same molecular vehicle — a significant conceptual disruption to conventional treatment design.
- Early human trials confirmed that tumors absorbed the compound strongly and that kidneys, liver, and pancreas were spared harm, but an unexpected accumulation of radiation in the stomach lining introduced a complication requiring resolution.
- Researchers are treating the gastric toxicity finding not as a failure but as a precise engineering target — a map of what the next generation of the compound must correct to become clinically viable.
- Publication in The Journal of Nuclear Medicine marks the first human evidence that this radiotheranostic strategy works in kidney cancer, positioning the approach for further dose optimization trials.
At a Beijing research hospital, scientists have fashioned a single molecular tool that can both find and destroy kidney cancer tumors — a convergence of diagnosis and therapy that medicine has long sought. The compound targets a protein that kidney cancer cells overproduce, allowing clinicians to first map the disease and then deliver radiation with unusual precision. For patients whose cancers have outrun immunotherapy and surgery, this approach represents not merely a new drug but a new philosophy of treatment — one that listens to the tumor's own biology before striking it.
At Peking Union Medical College Hospital in Beijing, a research team has developed a compound called 68Ga/177Lu-NYM096 that merges tumor detection and targeted radiation therapy into a single strategy. It works by binding to carbonic anhydrase IX, a protein that kidney cancer cells produce in abundance. Two radioactive forms of the same molecule serve distinct roles — one maps the disease through imaging, the other delivers therapeutic radiation directly to what the scan reveals.
Clear cell renal cell carcinoma accounts for the majority of kidney cancer cases, and many patients arrive with disease that has already spread or that has stopped responding to immunotherapy. For this population, meaningful alternatives have been scarce. Associate professor Wenjia Zhu led the team that engineered the compounds, and the dual-isotope design means that only patients whose tumors show strong uptake on the diagnostic scan proceed to treatment — a built-in filter that focuses radiation where it is most needed.
Animal studies showed the compound accumulating heavily in tumors and suppressing growth without apparent harm. Human trials followed, enrolling patients with metastatic disease that had progressed despite prior treatment. The results were largely encouraging: no damage was observed in the kidneys, liver, or pancreas. Tumors responded. But radiation was also accumulating in the stomach lining, producing toxicity that demands attention before the treatment can be widely adopted.
Li Huo, who directs the hospital's nuclear medicine department, framed the gastric finding as a roadmap rather than a setback — it identifies precisely what must be redesigned in the next iteration of the compound. The study, published in the September issue of The Journal of Nuclear Medicine, stands as the first human evidence that this radiotheranostic approach can work against kidney cancer, offering a potential path forward for patients who have run out of other options.
Researchers at Peking Union Medical College Hospital in Beijing have developed a new treatment approach for advanced kidney cancer that combines tumor detection and targeted radiation therapy in a single tool. The compound, called 68Ga/177Lu-NYM096, targets a protein called carbonic anhydrase IX that appears in high concentrations on kidney cancer cells. What makes this approach distinctive is that it uses two different radioactive forms of the same molecule—one for imaging to find tumors, another for delivering therapeutic radiation directly to them.
Clear cell renal cell carcinoma, or ccRCC, is the most common form of kidney cancer, representing between 70 and 80 percent of all cases. Many patients arrive at the clinic with disease that has already spread beyond the kidney or cannot be surgically removed. Others develop advanced disease after initial treatment. While newer immunotherapy combinations have helped some patients, a significant portion either do not respond to these drugs or suffer serious side effects from them. For these patients, new options are limited.
Wenjia Zhu, an associate professor of nuclear medicine at the hospital, led the team that engineered these small-molecule compounds to bind to the CAIX enzyme. The dual-isotope strategy allows clinicians to first image a patient's tumors with the diagnostic version, then, if the cancer shows up clearly, proceed to treatment with the therapeutic version. This precision reduces the amount of radiation exposure to healthy tissue compared to older approaches that cast a wider net.
The researchers tested the compound first in mice with kidney cancer tumors. The results were encouraging: the radioactive molecules accumulated heavily in tumors, and the therapeutic version suppressed tumor growth in a dose-dependent manner without causing harm. They then moved to human trials, enrolling patients with metastatic ccRCC whose disease had progressed despite standard treatment. These patients underwent imaging scans to map how the diagnostic compound distributed through their bodies and to measure radiation doses. Those whose tumors showed strong uptake of the imaging agent then received the therapeutic version, administered in escalating doses following a standard protocol used in early-stage drug testing.
The human data revealed both promise and a specific problem. The therapeutic compound showed no signs of damaging the kidneys, liver, or pancreas—a major advantage over some existing treatments that can harm these organs. Imaging after treatment showed that tumors were responding. However, patients experienced toxicity in the stomach lining, suggesting that radiation was accumulating there as an unintended consequence. This finding, while concerning, is not uncommon in radiotherapy and points to a clear target for refinement in future versions of the compound.
Li Huo, director of the nuclear medicine department at the same hospital, emphasized that the imaging agent successfully identified tumors with very high specificity, and that the early clinical results suggest targeted radiotherapy could become a viable option for selected patients who have exhausted other treatments. The gastric toxicity, he noted, represents both a challenge and a roadmap—it identifies exactly what needs to be engineered differently in the next generation of compounds to make the treatment safer. The research was published in the September issue of The Journal of Nuclear Medicine, marking the first human evidence that this particular radiotheranostic strategy can work in kidney cancer patients.
Citações Notáveis
These compounds allow for radiolabeling with both diagnostic and therapeutic radioisotopes to deliver treatment to patients more precisely—and safely.— Wenjia Zhu, associate professor of nuclear medicine at Peking Union Medical College Hospital
This study provides the first human evidence of the promise of this approach and highlights an important challenge—radiation to the stomach—that will help guide the development of safer future treatments.— Li Huo, director of the Department of Nuclear Medicine at Peking Union Medical College Hospital
Quer a matéria completa?
Leia o original em Medical Xpress ↗
Health & Medicine